— Research monograph
Semaglutide
The acylated GLP-1 receptor agonist benchmarked against TZ2 in SURPASS-2.
Updated
- Class
- Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (acylated GLP-1 analog)
- Half-life (research)
- ~7 days (engineered albumin binding; pharmacokinetic literature).
- Origin
- Developed by Novo Nordisk as a structurally engineered, albumin-binding analog of native GLP-1 designed for an extended half-life. The broader GLP-1 analog field grew out of incretin physiology characterized from the 1980s onward.
- Solubility
- Water-soluble. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures.
What is Semaglutide?
Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a 31-amino-acid incretin hormone. Engineering modifications — a C18 fatty-diacid side chain that promotes reversible binding to serum albumin, plus substitutions that resist DPP-4 degradation — give it a markedly longer circulating half-life than native GLP-1, a central focus of the analog literature.
In research, semaglutide is used as a reference GLP-1 receptor agonist for studying incretin signaling, pancreatic islet biology, and energy-metabolism models. It is a regulated therapeutic in approved human channels; the Merit Sciences offering is supplied strictly for research use and not for human or veterinary administration.
How does Semaglutide work?
Selective agonism at the GLP-1 receptor, a class B G-protein-coupled receptor. Receptor engagement modulates glucose-dependent insulin secretion, glucagon release, and central pathways implicated in satiety in preclinical models.
Research applications
- GLP-1 receptor signaling research
- Incretin and islet-biology models
- Energy-metabolism and appetite-pathway studies
- Comparative GLP-1 analog pharmacology
Semaglutide at Merit
Form & storage
Semaglutide ships as a sealed, lyophilized (freeze-dried) powder. Water-soluble. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures. Store sealed, light-protected, and follow your institution’s handling procedures for research materials.
Frequently asked questions
What is Semaglutide?
Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a 31-amino-acid incretin hormone. Engineering modifications — a C18 fatty-diacid side chain that promotes reversible binding to serum albumin, plus substitutions that resist DPP-4 degradation — give it a markedly longer circulating half-life than native GLP-1, a central focus of the analog literature. Merit supplies it as a lyophilized research compound for research use only, not for human or veterinary use.
How does Semaglutide work?
Selective agonism at the GLP-1 receptor, a class B G-protein-coupled receptor. Receptor engagement modulates glucose-dependent insulin secretion, glucagon release, and central pathways implicated in satiety in preclinical models. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.
What is the half-life of Semaglutide?
~7 days (engineered albumin binding; pharmacokinetic literature). Values reflect preclinical or research-context reports, not clinical pharmacokinetics.
Is Merit Semaglutide for human use?
No. It is sold strictly for research use only: not for human or veterinary use, and not for diagnostic or therapeutic use.
Is Semaglutide FDA-approved?
Semaglutide is FDA-approved only as specific branded prescription drug products; research material sold as semaglutide is not one of those products and is not FDA-approved. Supplied for research use only.
How is each batch of Semaglutide tested?
Every Merit batch is tested by an independent laboratory for identity and HPLC purity before it is listed, and Merit identifies batches by date rather than by lot number. Current certificates: Semaglutide 10 mg, July 2026 batch, 99.47% purity (meritsciences.com/coa/COA-2026-L_IYY7); Semaglutide 20 mg, July 2026 batch, 99.63% purity (meritsciences.com/coa/COA-2026-AX1BCL).
Regulatory status checked October 22, 2026 against: Drugs@FDA, WADA Prohibited List.
References
- The Discovery and Development of Liraglutide and Semaglutide. Knudsen LB, Lau J. Frontiers in Endocrinology, 2019 · doi:10.3389/fendo.2019.00155
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Nauck MA, Quast DR, Wefers J, et al.. Molecular Metabolism, 2021 · doi:10.1016/j.molmet.2020.101102
For research use only. Not for human or veterinary use. Reference information summarized from published literature, not medical advice.
— Keep reading